Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
NEWARK, Calif., Jan. 02, 2018 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Sujal Shah, President and Chief Executive Officer, will provide a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11, 2018 at 9:30am PT.
A live audio webcast of the presentation can be accessed through the Investors section of the CymaBay Therapeutics corporate website at http://ir.cymabay.com/events. The webcast will be archived on the corporate website for 90 days.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
